| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bde28565d28f037e78bf4a67776ee24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2012-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_253ed410e593d66558ee2be5cc42a5a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e048ae9c644f3e588d865e1a38ac7d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c96f8cff24ce378567994174507345e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b93652ac48e69e0d2c0443701357de5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17d2391090299208e29ca77de6374b65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_100e260dc3c6d33bed22d2dc367a1248
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d675c248b8f8657e92aea0e5aa683cf |
| publicationDate |
2013-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2886885-A1 |
| titleOfInvention |
Pde9i with imidazo pyrazinone backbone |
| abstract |
This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). |
| priorityDate |
2011-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |